Literature DB >> 8745224

Expression of inducible nitric oxide synthase in failing and non-failing human heart.

M Thoenes1, U Förstermann, W R Tracey, N M Bleese, A K Nüssler, H Scholz, B Stein.   

Abstract

Recently, a significant activity of inducible nitric oxide synthase (iNOS) has been reported in biopsies from failing hearts due to idiopathic dilated cardiomyopathy (IDC). Thus, a potential pathophysiological role of iNOS in IDC has been stated. In order to investigate, whether iNOS expression is of pathophysiological relevance in human heart failure, we measured iNOS protein expression and cGMP content in left ventricular myocardium from non-failing and failing human hearts. Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1). cGMP content was increased by 130% in septic hearts, whereas there was no cGMP increase in hearts with IDC. IHD and BMD compared to non-failing hearts. We conclude, that the induction of iNOS may play a role in contractile dysfunction observed in septic shock, but is unlikely to be of major pathophysiological importance in end-stage heart failure due to IDC, IHD, BMD and TCM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8745224     DOI: 10.1006/jmcc.1996.0016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  12 in total

1.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  The role of NOS in heart failure: lessons from murine genetic models.

Authors:  Imran N Mungrue; Mansoor Husain; Duncan J Stewart
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

3.  Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes.

Authors:  G Vandecasteele; I Verde; C Rücker-Martin; P Donzeau-Gouge; R Fischmeister
Journal:  J Physiol       Date:  2001-06-01       Impact factor: 5.182

4.  Sepsis-related microvascular myocardial damage with giant cell inflammation and calcification.

Authors:  Marcos A Rossi; Cláudio S Santos
Journal:  Virchows Arch       Date:  2003-04-26       Impact factor: 4.064

5.  Nitric oxide and promotion of cardiac myocyte apoptosis.

Authors:  Péter Andréka; Thanh Tran; Keith A Webster; Nanette H Bishopric
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

Review 6.  Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart.

Authors:  Soban Umar; Arnoud van der Laarse
Journal:  Mol Cell Biochem       Date:  2009-07-19       Impact factor: 3.396

7.  Inducible nitric oxide synthase (NOS2) expressed in septic patients is nitrated on selected tyrosine residues: implications for enzymic activity.

Authors:  Sophie Lanone; Philippe Manivet; Jacques Callebert; Jean-Marie Launay; Didier Payen; Michel Aubier; Jorge Boczkowski; Alexandre Mebazaa
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

8.  Septic cardiomyopathy - A not yet discovered cardiomyopathy?

Authors:  Ursula Muller-Werdan; Michael Buerke; Henning Ebelt; Konstantin M Heinroth; Anja Herklotz; Harald Loppnow; Martin Ruß; Frithjof Schlegel; Axel Schlitt; Hendrik B Schmidt; Gerold Söffker; Karl Werdan
Journal:  Exp Clin Cardiol       Date:  2006

Review 9.  Nitric oxide and cardiovascular protection.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

10.  Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function.

Authors:  Peter Krenek; Jana Kmecova; Dana Kucerova; Zuzana Bajuszova; Peter Musil; Andrea Gazova; Peter Ochodnicky; Jan Klimas; Jan Kyselovic
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.